"RxScorecard™ lets a biopharma company anticipate the most important factors impacting the clinical & economic value of pipeline and marketed drugs -- and then helps identify the necessary changes to the clinical development and commercial program to maximize that value for all stakeholders, especially including payers. It's a required, straightforward, objective strategic tool that allows us to quickly and effectively adapt to a rapidly changing and much more challenging market access environment."
Global Value/Market Access Lead Oncology Portfolio & Global Commercial Lead Oncology Biomarkers
Halozyme Therapeutics, Inc.
"RxScorecard™ provides a comprehensive, multi-pronged rubric assisting us in decision-making as we begin to move from a volume to value drug evaluation methodology."
Chronis H. Manolis, RPh
Vice President, Pharmacy
UPMC Health Plan
“With pharmacy costs increasing so quickly, there is increasing pressure for P&T and Technology Assessment Committees to consider the value as well as the clinical efficacy of the drugs under evaluation. By providing an objective framework for assessing value, RxScorecard™ fills a gap in the existing toolkit available to health plans. And with greater discussion around narrower formularies, RxScorecard™ becomes even more important.”
Michael S. Sherman, MD, MBA
Senior Vice President and Chief Medical Officer
Harvard Pilgrim Health Care
"We at GSK believe that it’s critical for the pharmaceutical industry to produce drugs that deliver value for patients, providers and payers. We have found RxScorecard™ to be an insightful framework for assessing and comparing the value of drugs, both marketed and developmental assets. The perspective it provides supports improved customer-focused development and commercialization, and we and our customers can benefit from its use.”